Division of Transplant SurgeryDepartment of SurgeryMayo ClinicPhoenixArizonaUSA.
Division of Gastroenterology and HepatologyMayo ClinicPhoenixArizonaUSA.
Liver Transpl. 2022 Nov;28(11):1726-1734. doi: 10.1002/lt.26461. Epub 2022 Apr 25.
Donation after circulatory death (DCD) liver transplantation (LT) outcomes have been attributed to multiple variables, including procurement surgeon recovery techniques. Outcomes of 196 DCD LTs at Mayo Clinic Arizona were analyzed based on graft recovery by a surgeon from our center (transplant procurement team [TPT]) versus a local procurement surgeon (non-TPT [NTPT]). A standard recovery technique was used for all TPT livers. The recovery technique used by the NTPT was left to the discretion of that surgeon. A total of 129 (65.8%) grafts were recovered by our TPT, 67 (34.2%) by the NTPT. Recipient age (p = 0.43), Model for End-Stage Liver Disease score (median 17 vs. 18; p = 0.22), and donor warm ischemia time (median 21.0 vs. 21.5; p = 0.86) were similar between the TPT and NTPT groups. NTPT livers had longer cold ischemia times (6.5 vs. 5.0 median hours; p < 0.001). Early allograft dysfunction (80.6% vs. 76.1%; p = 0.42) and primary nonfunction (0.8% vs. 0.0%; p = 0.47) were similar. Ischemic cholangiopathy (IC) treated with endoscopy occurred in 18.6% and 11.9% of TPT and NTPT grafts (p = 0.23). At last follow-up, approximately half of those requiring endoscopy were undergoing a stent-free trial (58.3% TPT; 50.0% NTPT; p = 0.68). IC requiring re-LT in the first year occurred in 0.8% (n = 1) of TPT and 3.0% (n = 2) of NTPT grafts (p = 0.23). There were no differences in patient (hazard ratio [HR], 1.95; 95% confidence interval [CI], 0.76-5.03; p = 0.23) or graft (HR, 1.99; 95% CI, 0.98-4.09; p = 0.10) survival rates. Graft survival at 1 year was 91.5% for TPT grafts and 95.5% for NTPT grafts. Excellent outcomes can be achieved using NTPT for the recovery of DCD livers. There may be an opportunity to expand the use of DCD livers in the United States by increasing the use of NTPT.
在循环死亡(DCD)肝移植(LT)中,供肝获取医师的恢复技术等多个变量会影响手术效果。分析了亚利桑那州梅奥诊所的 196 例 DCD LT 手术,将供肝由本中心的移植获取医师团队(TPT)获取的(TPT)与由当地获取医师(非 TPT [NTPT])获取的病例进行对比。所有 TPT 肝脏均采用标准恢复技术,而 NTPT 的恢复技术则由该医师自行决定。共有 129 例(65.8%)供肝由 TPT 获取,67 例(34.2%)由 NTPT 获取。TPT 与 NTPT 组的受体年龄(p=0.43)、终末期肝病模型评分(中位数 17 对 18;p=0.22)和供肝热缺血时间(中位数 21.0 对 21.5;p=0.86)相似。NTPT 肝脏的冷缺血时间更长(6.5 对 5.0 中位数小时;p<0.001)。早期移植物功能障碍(80.6%对 76.1%;p=0.42)和原发性无功能(0.8%对 0.0%;p=0.47)相似。内镜治疗的缺血性胆管炎(IC)分别发生于 TPT 和 NTPT 移植物的 18.6%和 11.9%(p=0.23)。在最后一次随访时,需要内镜治疗的患者中,约有一半正在进行无支架试验(58.3% TPT;50.0% NTPT;p=0.68)。在第一年,需要再次肝移植的 IC 发生在 0.8%(n=1)的 TPT 和 3.0%(n=2)的 NTPT 移植物中(p=0.23)。患者(风险比 [HR],1.95;95%置信区间 [CI],0.76-5.03;p=0.23)和移植物(HR,1.99;95%CI,0.98-4.09;p=0.10)的存活率无差异。TPT 移植物的 1 年移植物存活率为 91.5%,NTPT 移植物的 1 年移植物存活率为 95.5%。使用 NTPT 可获得 DCD 肝脏的出色效果。通过增加 NTPT 的使用,美国可能有机会扩大 DCD 肝脏的使用。